Bone markers in osteoporosis

Current Osteoporosis Reports

Volumn 7, Issue 3, 2009, Pages 84-90

  Garnero, Patrick ^a  

^a Synarc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K; CATHEPSIN K INHIBITOR; COLLAGEN; DENOSUMAB; DICKKOPF 1 PROTEIN; ESTROGEN; FRIZZLED PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; OSTEOPONTIN; PENTOSIDINE; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIALOPROTEIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WNT1 PROTEIN; ZOLEDRONIC ACID;

BONE DENSITY; BONE FRAGILITY; BONE METABOLISM; BONE TURNOVER; DIAGNOSTIC ACCURACY; DISEASE MARKER; GENE FUNCTION; GENE OVEREXPRESSION; HIP FRACTURE; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; REVIEW; SPINE FRACTURE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BODY MASS INDEX; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT;

EID: 72449151196     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-009-0014-3     Document Type: Review

References (56)

1. Garnero P, Delmas PD: Investigation of bone: biochemical markers. In Rheumatology, 4rd edn. Edited by Hochberg MC, Silman AJ, Smolen JS, et al.: London: Harcourt Health Sciences Ltd.; 2007:1943-1953.
2. P. Szulc P.D. Delmas 2008 Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis Osteoporosis Int 19 1683 1704 10.1007/s00198-008-0660-9 1:CAS:528: DC%2BD1cXht12kur7P
3. S. Cremers P. Garnero 2006 Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls Drugs 66 2031 2058 17112299 10.2165/00003495- 200666160-00001 1:CAS:528:DC%2BD2sXmvFOjsg%3D%3D (Pubitemid 46372356)
4. P. Garnero 2008 New biochemical markers of bone turnover IBMS BoneKEy 5 84 102 10.1138/20080302
5. A.K. Srivastava F.R. Mohan F.R. Singer, et al. 2002 A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients Bone 31 62 69 12110414 10.1016/S8756-3282(02)00793-7 1:CAS:528:DC%2BD38XltFWgsr4%3D (Pubitemid 34754427)
6. N.S. Fedarko A. Jain A. Karadag, et al. 2001 Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer Clin Cancer Res 7 4060 4066 11751502 1:CAS:528:DC%2BD38XltFSitA%3D%3D
7. Y. Kudo B.S. Siriwardena H. Hatano, et al. 2007 Periostin: novel diagnostic and therapeutic target for cancer Histol Histopathol 22 1167 1174 17616943 1:CAS:528:DC%2BD2sXhtlaks7nK
8. J. Lenora K.K. Ivaska K.J. Obrant, et al. 2007 Prediction of bone loss using biochemical markers of bone turnover Osteoporos Int 18 1297 1305 17440674 10.1007/s00198-007-0379-z 1:STN:280:DC%2BD2svptFajuw%3D%3D (Pubitemid 47300283)
9. P. Gerdhem K.K. Ivaska S.L. Alatalo, et al. 2004 Biochemical markers of bone metabolism and prediction of fracture in elderly women J Bone Miner Res 19 386 393 15040826 10.1359/JBMR.0301244 1:CAS:528:DC%2BD2cXisFCrsLg%3D (Pubitemid 38787393)
10. H. Sasaki C.Y. Yu M. Dai, et al. 2003 Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer Breast Cancer Res Treat 77 245 252 12602924 10.1023/A:1021899904332 1:CAS:528:DC%2BD3sXivFWr (Pubitemid 36197639)
11. J.M. Halleen S.L. Alatalo H. Suominen, et al. 2000 Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption J Bone Miner Res 15 1337 1345 10893682 10.1359/jbmr.2000.15.7.1337 1:CAS:528:DC%2BD3cXltFSiurs%3D
12. R.A. Hannon J.A. Clowes A.C. Eagleton, et al. 2004 Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption Bone 34 187 194 14751577 10.1016/j.bone.2003.04.002 1:CAS:528:DC%2BD2cXnvVCguw%3D%3D (Pubitemid 38142448)
13. A.E. Kearns S. Khosla P. Kostenuik 2008 RANKL and OPG regulation of bone remodeling in health and disease Endocr Rev 29 155 192 18057140 10.1210/er.2007-0014 1:CAS:528:DC%2BD1cXltlOhsr0%3D
14. A. Rogers R. Eastell 2005 Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment J Clin Endocrinol Metab 90 6323 6331 16105967 10.1210/jc.2005-0794 1:CAS:528:DC%2BD2MXht1altLzO (Pubitemid 41606564)
15. T.F. Day X. Guo L. Garrett-Beal, et al. 2005 Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis Dev Cell 8 739 750 15866164 10.1016/j.devcel.2005.03.016 1:CAS:528:DC%2BD2MXkslentbc%3D (Pubitemid 40585296)
16. N. Voorzanger-Rousselot F. Journe V. Doriath, et al. 2009 Assessment of circulating Dickkopf-1 with a new two site immunoassay in healthy subjects and women with breast cancer and bone metastases Calcif Tissue Int 84 348 354 19252761 10.1007/s00223-009-9225-y 1:CAS:528:DC%2BD1MXltV2htrc%3D
17. E. Tian F. Zhan R. Walker, et al. 2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma N Engl J Med 349 2483 2494 14695408 10.1056/NEJMoa030847 1:CAS:528: DC%2BD3sXhtVWit7zO (Pubitemid 38010074)
18. N. Voorzanger-Rousselot D. Goehrig F. Journe, et al. 2007 Increased dickkopf-1 (Dkk-1) expression in breast cancer bone metastases Br J Cancer 97 964 970 17876334 1:CAS:528:DC%2BD2sXhtFSnurfM
19. D. Diarra M. Stolina K. Polzer, et al. 2007 Dickkopf-1 is a master regulator of joint remodeling Nat Med 13 156 163 17237793 10.1038/nm1538 1:CAS:528:DC%2BD2sXhsVyktbY%3D (Pubitemid 46245765)
20. N.E. Lane M.C. Nevitt L.Y. Lui, et al. 2007 Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women Arthritis Rheum 56 3319 3325 17907185 10.1002/art.22867 1:CAS:528:DC%2BD2sXht12rtLbM (Pubitemid 47585426)
21. N. Voorzanger-Rousselot D. Goehrig T. Facon, et al. 2009 Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma Br J Haematol 145 264 266 19210508 10.1111/j.1365-2141.2009.07587.x 1:CAS:528:DC%2BD1MXltlSmtrg%3D
22. Leeming DJ, Henriksen K, Byrjalsen I, et al.: Is bone quality associated with bone remodeling. Osteoporos Int 2009, Mar 28 (Epub ahead of print).
23. M. Yamamoto T. Yamaguchi M. Yamauchi, et al. 2008 Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes J Clin Endocrinol Metab 93 1013 1019 18160470 10.1210/jc.2007-1270 1:CAS:528:DC%2BD1cXjsFymsrc%3D
24. Schwartz AV, Garnero P, Hillier AT, et al.: Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009, Apr 21 (Epub ahead of print).
25. P. Garnero E. Gineyts A.V. Schaffer, et al. 1998 Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's Disease Arthritis Rheum 41 354 360 9485094 10.1002/1529-0131(199802)41: 2<354::AID-ART20>3.0.CO;2-5 1:CAS:528:DyaK1cXhtlSmtL0%3D (Pubitemid 28087704)
26. P. Alexandersen P. Peris N. Guanabens, et al. 2005 Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone J Bone Miner Res 20 588 595 15765177 10.1359/JBMR.041212 1:CAS:528:DC%2BD2MXnt1ymsLg%3D (Pubitemid 40393066)
27. D.J. Leeming A. Hegele I. Byrjalsen, et al. 2008 Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers Cancer Epidemiol Biomarkers Prev 17 1269 1276 18483350 10.1158/1055-9965.EPI-07-2697 1:CAS:528:DC%2BD1cXmtVCltr0%3D
28. P. Garnero A.M. Schott D. Prockop G. Chevrel 2009 Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations Bone 44 461 466 19071236 10.1016/j.bone.2008.11.006 1:CAS:528:DC%2BD1MXhvF2qsbs%3D
29. P. Garnero P. Cloos E. Sornay-Rendu, et al. 2002 Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study J Bone Miner Res 17 826 833 12009013 10.1359/jbmr.2002.17.5.826 1:CAS:528:DC%2BD38XktVSktro%3D
30. I. Byrjalsen D.J. Leeming P. Qvist, et al. 2008 Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies Osteoporos Int 19 339 348 17846859 10.1007/s00198-007-0462-5 1:CAS:528:DC%2BD1cXhtlOqs7s%3D (Pubitemid 351199183)
31. M.A. Karsdal I. Byrjalsen D.J. Leeming, et al. 2008 The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality Osteoporos Int 19 1355 1361 18385918 10.1007/s00198-008-0603-5 1:CAS:528:DC%2BD1cXps1Srsb0%3D
32. P. Garnero D.C. Bauer E. Mareau, et al. 2008 Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study J Bone Miner Res 23 1442 1448 18442311 10.1359/jbmr.080413 1:CAS:528:DC%2BD1cXhtFSlurvL
33. P. Garnero P. Vergnaud N. Hoyle 2008 Evaluation of a fully automated serum assay for total N terminal propeptide of type I collagen in postmenopausal osteoporosis Clin Chem 54 188 196 17998267 10.1373/clinchem.2007.094953 1:CAS:528:DC%2BD1cXmtFersg%3D%3D (Pubitemid 351182613)
34. S. Bhattacharyya E.R. Siegel S.J. Achenbach, et al. 2008 Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women J Bone Miner Res 23 1106 1117 18302502 10.1359/jbmr.080235 1:CAS:528: DC%2BD1cXovFers7c%3D (Pubitemid 351915733)
35. A. Claudon P. Vergnaud C. Valverde, et al. 2008 A new automated multiplex assay for bone turnover markers in osteoporosis Clin Chem 54 1554 1563 18676587 10.1373/clinchem.2008.105866 1:CAS:528:DC%2BD1cXhtVGqsb3K
36. J.A. Kanis E.V. McCloskey H. Johansson, et al. 2008 Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK Osteoporos Int 19 1395 1408 18751937 10.1007/s00198-008-0712-1 1:STN:280:DC%2BD1crnvFelug%3D%3D
37. J.J. Stepan 2000 Prediction of bone loss in postmenopausal women Osteoporos Int 11 Suppl6 S45 S54 11193239 10.1007/s001980070005 (Pubitemid 32039512)
38. K.K. Ivaska J. Lenora P. Gerdhem, et al. 2008 Serial assessment of serum bone metabolism markers identifies women with highest rate of bone loss and osteoporosis risk J Clin Endocrinol Metab 93 2622 2632 18460567 10.1210/jc.2007-1508 1:CAS:528:DC%2BD1cXoslyku78%3D (Pubitemid 352008529)
39. P. Garnero P.D. Delmas 2004 Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women J Musculoskel Neuron Interact 4 50 63 1:STN:280: DC%2BD2cnjvFSrtA%3D%3D
40. O. Johnell A. Oden C. De Laet, et al. 2002 Biochemical markers and the assessment of fracture probability Osteoporos Int 13 523 526 12111011 10.1007/s001980200068 1:STN:280:DC%2BD38zmslSntA%3D%3D (Pubitemid 34790623)
41. E. Sornay-Rendu F. Munoz P. Garnero, et al. 2005 The identification of osteopenic women at high risk of fracture: The OFELY study J Bone Miner Res 20 1813 1819 16160738 10.1359/JBMR.050609 (Pubitemid 41361882)
42. M.J. Seibel V. Naganathan I. Barton A. Grauer 2004 Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate J Bone Miner Res 19 323 329 14969403 10.1359/JBMR.0301231 1:CAS:528:DC%2BD2cXhs1elsrs%3D (Pubitemid 38116747)
43. D.C. Bauer P. Garnero M.C. Hochberg, et al. 2006 Pre-treatment bone turnover and fracture efficacy of alendronate: the Fracture Intervention Trial J Bone Miner Res 21 292 299 16418785 10.1359/JBMR.051018 1:CAS:528: DC%2BD28Xhs1Kmu7Y%3D (Pubitemid 43265295)
44. P. Chen J.H. Satterwhite A.A. Licata, et al. 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J Bone Miner Res 20 962 970 15883636 10.1359/JBMR.050105 1:CAS:528:DC%2BD2MXlsFehtr0%3D (Pubitemid 40712820)
45. D.C. Bauer P. Garnero J.P. Bilezikian, et al. 2006 Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis J Clin Endocrinol Metab 91 1370 1375 16449339 10.1210/jc.2005-1712 1:CAS:528:DC%2BD28XjvFOksb0%3D
46. P.D. Delmas A.A. Licata J.Y. Reginster, et al. 2006 Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover Bone 39 237 243 16563890 10.1016/j.bone.2006.02.003 1:CAS:528:DC%2BD28Xls1ejt70%3D (Pubitemid 43851376)
47. E. Seeman 2007 Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 4 308 317 10.1016/j.bone.2007.06.010 (Pubitemid 47199158)
48. S. Sarkar J.Y. Reginster G.G. Crans, et al. 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk J Bone Miner Res 19 394 401 15040827 10.1359/JBMR.0301243 (Pubitemid 38787394)
49. R. Eastell I. Barton R.A. Hannon, et al. 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 1056 12817758 10.1359/jbmr.2003.18.6.1051 1:CAS:528:DC%2BD3sXkslOhsb0%3D (Pubitemid 37294942)
50. R. Eastell R.A. Hannon P. Garnero, et al. 2007 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis J Bone Miner Res 22 1656 1660 17931100 10.1359/jbmr.07090b (Pubitemid 351235131)
51. D.C. Bauer D.M. Black P. Garnero, et al. 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial J Bone Miner Res 19 1250 1258 15231011 10.1359/JBMR.040512 (Pubitemid 41094365)
52. P.D. Delmas F. Munoz F. Cosman, et al. 2008 Relationship of bone turnover marker (PINP) and changes in femoral neck bone mineral density to fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg (ZOL): the Horizon-PFT study [abstract] J Bone Miner Res 23 S9
53. S.J. Glover P. Garnero K. Naylor, et al. 2008 Establishing a reference range for bone turnover markers in young, healthy women Bone 42 623 630 18289953 10.1016/j.bone.2007.12.218 1:CAS:528:DC%2BD1cXjs1Whur0%3D
54. S. Glover M. Gall O. Schoenborn-Kellenberger, et al. 2009 Establishing a reference interval for bone Turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA J Bone Miner Res 24 389 397 18665786 10.1359/jbmr.080703
55. J.A. Clowes N.F. Peel R. Eastell 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J Clin Endocrinol Metab 89 1117 1123 15001596 10.1210/jc.2003-030501 1:CAS:528:DC%2BD2cXisVWrtbo%3D (Pubitemid 38368399)
56. P.D. Delmas B. Vrijens R. Eastell, et al. 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 4 1296 1304 10.1210/jc.2006-1526 (Pubitemid 46556401)